Diabetes Protects from Prostate Cancer by Downregulating Androgen Receptor: New Insights from LNCaP Cells and PAC120 Mouse Model

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Barbosa Desongles, Anna ^a   Hernández, Cristina ^a   De Torres, Ines ^b   Munell, Francina ^b   Poupon, Marie France ^c   Simó, Rafael ^a   Selva, David M ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MESSENGER RNA; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL STRAIN LNCAP; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; MICE; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STREPTOZOCIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883818991     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074179     Document Type: Article

References (57)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-36.
2. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. CA Cancer Journal for Clinicians. 60(4): 207-221.
3. Grace Sun, Sangeeta R Kashyap (2011) Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations. J Nutr Metab. 708183.
4. Kasper JS, Liu Y, Giovannucci E, (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 124(6): 1398-403.
5. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, et al. (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 169(8): 937-45.
6. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA, (2011) Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 128(3): 635-43.
7. Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, et al. (2011) Association of diabetes mellitus with prostate cancer: nested case-control study (prostate testing for cancer and treatment study). Int J Cancer. 128 (2): 440-6.
8. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, et al. (2005) Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 161: 147-152.
9. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, et al. (2011) Diabetes and prostate cancer in the REDUCE trial. Prostate Cancer and Prostatic Diseases 14: 326-331.
10. Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, et al. (2010) History of diabetes mellitus and the risk of prostate cancer: the Osaki Cohort Study. Cancer Causes and Control. 21: 977-983.
11. Fukushima H, Masuda H, Kawakami S, Ito M, Sakura M, et al. (2012) Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/ml. Urology. 79(6): 1329-34.
12. Müller H, Raum E, Rotenbacher D, Stegmaier C, Brenner H, (2009) Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev. 18: 1350-1356.
13. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, et al. (2011) The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted county study. Urology. 77: 137-141.
14. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, et al. (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Pre. 15: 1977-1983.
15. Grossmann M, Wittert G, (2012) Androgens, Diabetes and Prostate cancer. Endocr Relat Cancer. 19(5): F47-62.
16. Frayling T, Colhoun H, Florez J, (2008) A genetic link between type 2 dibetes and prostate cancer. Diabetologia. 51: 1757-60.
17. Pierce BL, Ahsan H, (2010) Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered. 69(3): 193-201.
18. Meyer TE, Boerwinkle E, Morrison AC, Volcik KA, Sanderson M, et al. (2010) Diabetes genes and prostate cancer in the Arteriosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev. 19 (2): 558-565.
19. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, et al. (2007) Two variants of chromosome 17 confers prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 39: 977-983.
20. Olson NC, Callas PW, Hanley AJ, Festa A, Haffner SM, et al. (2012) Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab. 97(3): 1032-40.
21. Simó R, Barbosa-Desongles A, Lecube A, Hernandez C, Selva DM, (2012) Potencial role of tumor necrosis factor-α in downregulating sex hormone-binding globulin. Diabetes. 61(2): 372-82.
22. Simó R, Barbosa-Desongles A, Sáez-Lopez C, Lecube A, Hernandez C et al. (2012) Molecular Mechanisms of TNFα-induced Down-Regulation of SHBG Expresión. Mol Endocrinol. 26(3): 438-46. Epub 2012 Feb 2.
23. Meyer TE, Chu LW, Li Q, Yu K, Rosenberg PS, et al. (2012) The association between inflammation-related genes and serum androgen levels in men: the prostate, ling, colorectal, and ovarian study. Prostate. 72(1): 65-71.
24. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal, et al, (1983) LNCaP model of human prostatic carcinoma. Cancer Res. 43: 1809-1818.
25. Ko S, Shi L, Kim S, Song CS, Chatterjee B, (2008) Interplay of nuclear factor-κB and B-myb in the negative regulation of androgen receptor expression by tumour necrosis factor α. Mol Endocrinol. 22: 273-86.
26. Pieper GM, (1997) Riaz-ul-Hag (1997) Activation of nuclear factor-kappaB in cultured endotelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol. 30: 528-32.
27. Sheu ML, Ho FM, Yang RS, Chao KF, Lin WW, et al. (2005) High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol. 25(3): 539-45.
28. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M, (2002) Activation of Nuclear Factor-κB Induced by Diabetes and High Glucose Regulates a Proapoptotic Program in Retinal Pericytes. Diabetes. 51(7): 2241-8.
29. Kowluru RA, Koppolu P, Chakrabarti S, Chen S, (2003) Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res. 37(11): 1169-80.
30. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B, (2000) Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res. 87: 746-752.
31. Supakar PC, Jung MH, Song CS, Chatterjee B, Roy AK, (1995) Nuclear factor NF-κB activity increases during the age-dependent desensitization of the liver. J Biol Chem. 270: 837-42.
32. de Pinieux G, Legrier ME, Poirson-Bichat F, Courty Y, Bras-Gonçalves R, et al. (2001) Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol. 159(2): 753-64.
33. Poupon MF, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, et al. (1993) Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst. 85(24): 2023-9.
34. Bansal D, Bhansati A, Kapil G, Undela K, Tiwari P (2012) Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. [Epub ahead of print].
35. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, et al. (2000) Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 7: 997-1007.
36. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ, (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62: 1008-1013.
37. Liao X, Tang S, Thrasher JB, Griebling TL, Li B, (2005) Small interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther. 4: 505-515.
38. Polychronakos C, Janthly U, Lehoux JG, Koutsilieris M, (1991) Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate. 19: 313-21.
39. Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, et al. (2011) Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res. 71(17): 5754-64.
40. Hsing A, Sakoda L, Chua SJ, (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 86: 843-57.
41. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E, (2008) Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control. 19(7): 703-10.
42. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, et al. (2005) Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer. 103(1): 76-84.
43. Goldenberg SL, Koupparis A & Robinson ME, (2011) Differing levels of testosterone and the prostate: a physiological interplay. Nature Reviews Urology. 8: 365-377.
44. Morgentaler A, (2011) Testosterone and prostate cancer: what are the risks for middle-aged men? Urologic Clinics of North America. 38: 119-124.
45. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, et al. (2008) The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 15 68(16): 6762-9.
46. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, et al. (2007) Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 16(1): 63-9.
47. Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC, et al. (2011) Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiol Biomarkers Prev. 20(5): 844-53.
48. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T, (2000) Tumor necrosis factor-α represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol. 164: 800-5.
49. Wang D, Montgomery RB, Schmidt LJ, Mostaghel EA, Huang H, et al. (2009) Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res. 69(24): 9448-56.
50. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM, (1996) Suppression of TNF-α-induced apoptosis by NF-κB. Science. 274: 787-9.
51. Chopra DP, Menard RE, Januszewski J, Mattingly RR, (2004) TNF-α-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett. 203: 145-54.
52. Seo SI, Song SY, Kang MR, Kim MS, Oh JE, et al. (2009) Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers. APMIS. 117(8): 623-8.
53. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, et al. (2004) Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res. 1 10(7): 2466-72.
54. Ismail HA, Lessard L, Mes-Masson AM, Saad F, (2004) Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate. 15 58(3): 308-13.
55. Mimeault M, Johansson SL, Batra SK, (2012) Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies. PLoS One. 7(2): e31919.
56. Hales DB, (2002) Testicular macrophage modulation of Leydig cell steroidogenesis. J Reprod Immunol. 57: 3-18.
57. Maggio M, Basaria S, Ceda GP, Ble A, Ling SM, et al. (2005) The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest. 28: 116-119.